Multiple sclerosis (MS) as a chronic disease presents a vast variability of neurological symptoms. Spasticity is one of the most
common symptoms. The principle indication to treat spasticity is disability or handicap of capabilities. All pharmacological methods are
attributed to a basic physical management. Different effective treatment schemes have been established. Nevertheless the value of intrathecal
triamcinolone acetonid (TCA) in MS is still a controversial issue. Bearing in mind that only limited data are available and due to
its invasive application form repeated TCA administration can be recommended as one therapy option in MS with a progressive clinical
course and predominantly spinal symptoms.
Keywords: Multiple sclerosis, intrathecal steroids, triamcinolone acetonide, spasticity, neurological symptoms, inflammatory disease, neuron, methylprednisolone acetate (MPA), steroids, intrathecal.
Rights & PermissionsPrintExport